335 related articles for article (PubMed ID: 32167790)
21. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
22. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
24. Safety concerns with current treatments for psoriasis in the elderly.
Di Caprio R; Caiazzo G; Cacciapuoti S; Fabbrocini G; Scala E; Balato A
Expert Opin Drug Saf; 2020 Apr; 19(4):523-531. PubMed ID: 32056449
[No Abstract] [Full Text] [Related]
25. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
26. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
27. The safety of brodalumab for the treatment of psoriasis.
Iznardo H; Puig L
Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
[No Abstract] [Full Text] [Related]
28. Systemic therapies for psoriasis: an evidence-based update.
Sandoval LF; Pierce A; Feldman SR
Am J Clin Dermatol; 2014 Jul; 15(3):165-80. PubMed ID: 24496885
[TBL] [Abstract][Full Text] [Related]
29. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
30. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
32. Emerging systemic drugs in the treatment of plaque psoriasis.
Balogh EA; Bashyam AM; Ghamrawi RI; Feldman SR
Expert Opin Emerg Drugs; 2020 Jun; 25(2):89-100. PubMed ID: 32192366
[TBL] [Abstract][Full Text] [Related]
33. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
34. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
36. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
37. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
38. Apremilast for the treatment of psoriasis.
Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
[TBL] [Abstract][Full Text] [Related]
39. Biological therapy in genital psoriasis in women.
Burlando M; Herzum A; Carmisciano L; Cozzani E; Parodi A
Dermatol Ther; 2020 Jan; 33(1):e13110. PubMed ID: 31595647
[TBL] [Abstract][Full Text] [Related]
40. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
